ArticlePLoS medicine2017
Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden.
Article in PLoS medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Screening for the prevention and early detection of cervical cancer: systematic reviews to inform an update to recommendations by the Canadian Task Force on Preventive Health Care.Systematic reviews · 2025Pooled it
- Value of a catch-up HPV test in women aged 65 and above: A Danish population-based nonrandomized intervention study.PLoS medicine · 2023Trial
- Non-speculum sampling approaches for cervical screening in older women: randomised controlled trial.The British journal of general practice : the journal of the Royal College of General Practitioners · 2022Trial
- Long-Term Regional Pathology-Detection Trends in High-Grade Cervical Lesions and Cervical Squamous Cell Carcinoma Among Women Aged 40-69 Years in Northern Norway, 1998-2025.Diagnostics (Basel, Switzerland) · 2026Article
- Global, regional, and national epidemiology of cervical cancer in elderly women from 1990 to 2021 and its prediction to 2035.BMC public health · 2025Article
- Risk of CIN2+ in women aged >60 years with abnormal cervical cancer screening: a multicenter retrospective cohort study from the Thai Gynecologic Cancer Society research group.Journal of gynecologic oncology · 2025Article
- Nationwide registry-based trial of risk-stratified cervical screening.International journal of cancer · 2025Article
- Exploring public preferences and demand for ovarian cancer screening: a discrete choice experiment.Frontiers in oncology · 2025Article
- Article
- Missed diagnosis of pelvic organ prolapse complicated with cervical cancer: a retrospective case series of five patients and review of literature.Gynecology and pelvic medicine · 2024Article
- Impact of cervical screening by human papillomavirus genotype: Population-based estimations.PLoS medicine · 2023Article
- Effect of Test History at Ages 50-64 on Later Cervical Cancer Risk: A Population-based Case-control Study.Cancer research communications · 2023Article
- Experiences of human papillomavirus self-sampling by women >60 years old: A qualitative study.Health expectations : an international journal of public participation in health care and health policy · 2023Article
- Effectiveness of Cervical Testing in and outside a Screening Program-A Case-Control Study.Cancers · 2022Article
- Article
- Time Trends for Incidence and Net Survival of Cervical Cancer in Sweden 1960-2014-A Nationwide Population-Based Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Health impacts of COVID-19 disruptions to primary cervical screening by time since last screen: A model-based analysis for current and future disruptions.medRxiv : the preprint server for health sciences · 2022Article
- Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment.BMC cancer · 2022Article
- Age-specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross-sectional study.Cancer communications (London, England) · 2022Article
- Impact of changes to cervical screening guidelines on age and interval at which women are tested: Population-based study.Journal of medical screening · 2021Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe relatively high incidence of cervical cancer in women at older ages is a continuing concern in countries with long-established cervical screening. Controversy remains on when and how to cease screening. Existing population-based studies on the effectiveness of cervical screening at older ages have not considered women's screening history. We performed a nationwide cohort study to investigate the incidence of cervical cancer after age 60 years and its association with cervical screening at age 61-65, stratified by screening history at age 51-60. METHODS AND
findingsUsing the Total Population Register, we identified 569,132 women born between 1 January 1919 and 31 December 1945, resident in Sweden since age 51. Women's cytological screening records, cervical cancer occurrence, and FIGO stage (for those diagnosed with cancer) were retrieved from national registers and medical charts. We calculated the cumulative incidence of cervical cancer from age 61 to age 80 using a survival function considering competing risk, and estimated the hazard ratio (HR) of cervical cancer in relation to screening status at age 61-65 from Cox models, adjusted for birth cohort and level of education, conditioning on women's screening history in their 50s. In women unscreened in their 50s, the cumulative incidence up to age 80 was 5.0 per 1,000 women, and screening at age 61-65 was associated with a lower risk for cervical cancer (HR = 0.42, 95% CI 0.24-0.72), corresponding to a decrease of 3.3 cancer cases per 1,000 women. A higher cumulative incidence and similarly statistically significant risk decrease was seen for women with abnormal smears in their 50s. In women adequately or inadequately screened with only normal results between age 51 and age 60, the cumulative incidence of cervical cancer from age 61 to 80 was 1.6 and 2.5 per 1,000 women, respectively, and further screening at age 61-65 was not associated with statistically significant decreases of cervical cancer risk up to age 80, but with fewer cancer cases of advanced stages at age 61-65. Adjustment for potential lifestyle confounders was limited.
conclusionsIn this study, cervical screening with cytology at age 61-65 was associated with a statistically significant reduction of subsequent cervical cancer risk for women who were unscreened, or screened with abnormalities, in their 50s. In women screened with normal results in their 50s, the risk for future cancer was not sizeable, and the risk reduction associated with continued screening appeared limited. These findings should inform the current debate regarding age and criteria to discontinue cervical screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.